Skip to Content

    Soliris, this biopharma company’s lucrative drug for rare blood disorders, helped infuse 24% sales growth in the second quarter of 2015.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Location
    Cheshire, CT
    Industry
    Pharmaceuticals
    Sector
    Health Care
    Fortune 500 Rank941
    Fortune 500 Profilehttp://fortune.com/fortune500/alexion-pharmaceuticals-941/
    Current Streak2
    Years on List4
    CEO
    David L. Hallal
    Websitehttp://www.alxn.com

    Revenue, Net Income

    Revenue Past Four Quarters2,267
    Net Income Past Four Quarters589

    Growth Rates

    EPS 3 yr Annual Growth Rate43%
    Rev 3 yr Annual Growth Rate40%
    Total Return 3 yr Annual Rate22%
    Beat S&P 3 yr Total Return?
    yes

    Rank

    EPS Growth Rank53
    Revenue Growth Rank25
    Total Return Rank
    86